AbbVie (NYSE: ABBV) has finalized its $10.9 billion acquisition of Apogee Therapeutics (NASDAQ: APGE), a move that the company says will not boost its bottom line for another six years. The deal, which was announced in June 2026, is expected to reduce adjusted earnings by $0.46 per share in 2027, with accretion not anticipated until 2032, according to a September 3 completion notice.
This timeline makes the acquisition a test of investor patience rather than an immediate profit driver. Shareholders are effectively buying a long-dated option in immunology, with the company’s current blockbuster drugs—Skyrizi and Rinvoq—expected to fund the wait. AbbVie’s shares closed Friday at $256.46, down 1.4% for the session, but remain 18.5% above their June 18 close, the last trading day before the deal was made public. U.S. markets were closed Monday for Labor Day, with trading resuming Tuesday.
CEO Robert Michael called completion “an important step in further strengthening AbbVie’s leadership in immunology and advancing our long-term growth strategy.” The company also reaffirmed its 2026 adjusted EPS guidance of $13.87 to $14.07.
Immunology franchise powers the bet
AbbVie enters this gamble with considerable operating momentum. Second-quarter immunology revenue rose 15.1% year over year to $8.79 billion, driven by Skyrizi’s 24.4% surge to $5.51 billion and Rinvoq’s 24.5% jump to $2.53 billion. Meanwhile, Humira—once the company’s engine—continued its decline, falling 35.9% to $756 million. The new generation of drugs is growing faster than the old blockbuster is shrinking, providing the cash flow to support the Apogee bet.
Apogee brings no approved products to AbbVie. Its lead candidate, zumilokibart, is an experimental antibody for atopic dermatitis (eczema) entering late-stage trials. The purchase price was $135.11 per share in cash, valuing the deal at $10.1 billion net of acquired cash and marketable securities. AbbVie plans to fund the acquisition with debt, having arranged a $10 billion 364-day unsecured term loan. As of June 30, the company held $6.57 billion in cash and $70.82 billion in total debt. Management aims to reduce net leverage to two times within two to three years.
Clinical promise and early data
Zumilokibart’s Phase 2 study enrolled 346 adults with moderate-to-severe atopic dermatitis. At week 16, 65.9% of patients on the selected mid-dose achieved EASI-75, a measure of skin clearance, versus 23.4% for placebo. The trial met primary and secondary endpoints, according to Apogee’s May data release. However, cross-trial comparisons against existing biologic therapies were not head-to-head, and the company plans three Phase 3 studies, each with roughly 400 patients, to confirm efficacy and safety.
The potential for less frequent dosing—every three or six months—could differentiate zumilokibart in a crowded market. Jonathan Silverberg, a dermatology professor at George Washington University, noted the “potential for sustained disease control with less frequent dosing.” But that convenience factor remains unproven in larger trials.
William Blair analyst Matt Phipps suggested the acquisition allows AbbVie to “accelerate Phase 3 development” and potentially reduce royalties owed to Blackstone, a key financier of Apogee’s earlier work. Apogee reported a net loss of $85.9 million in the June quarter, with $67.3 million spent on research and development.
Long road to accretion
AbbVie’s management estimates the deal will reduce adjusted EPS by $0.14 in 2026 and $0.46 in 2027. The company sees potential first approval for atopic dermatitis in early 2030, with meaningful earnings contribution starting in 2032. That timeline depends on successful Phase 3 data, regulatory review, and market adoption.
For investors, the calculus is clear: the current immunology franchise must keep delivering while the pipeline matures. If Skyrizi and Rinvoq growth falters, or if interest costs rise, the payoff could be pushed further out. Conversely, a successful launch of zumilokibart could open a new revenue stream in a high-demand therapeutic area. AbbVie’s stock performance suggests shareholders are willing to wait—but the wait is long, and the risk of clinical failure remains real.
